Jean-Philippe Alex Combal

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Fournier Pharma SA manufactures pharmaceutical products. The firm is also in the engaged in the research, development, production and marketing of molecules. The company has operations in Canada, China, Algeria, Bulgaria, Thailand and Turkey. It was founded in 1880 and is headquartered in Chenôve, France.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.

Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France.

Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.